leo 29102
Small moleculeexperimental
Clinical trial activity
8 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2009 (NCT00891709)
Timeline
Indications
Mechanism of action
PDE4A inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- 2-(6-(2-(3,5-dichloro-4-pyridyl)acetyl)-2,3-dimethoxyphenoxy)-n-propylacetamide
- leo 29102
- leo 29102
- leo 29102
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01466478 | Phase 1 | Nov 1, 2011 | Leo Pharma |
| NCT01447758 | Phase 1 | Sep 1, 2011 | J. W. Goethe University, Leo Pharma |
| NCT01423656 | Phase 1 | Aug 1, 2011 | Covance, Leo Pharma |
| NCT01037881 | Phase 2 | Dec 1, 2009 | Leo Pharma, University of Helsinki |
| NCT01005823 | Phase 1 | Oct 1, 2009 | Leo Pharma, Pharmaceutical Research Associates, Inc. (PRA) |
| NCT00958516 | Phase 1 | Sep 1, 2009 | Leo Pharma |
| NCT00875277 | Phase 2 | Apr 1, 2009 | Leo Pharma |
| NCT00891709 | Phase 1 | Mar 1, 2009 | LCG Bioscience, Leo Pharma |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Leo Pharma | For profit | 8 | 8 | 2 | 2009 |
| Covance | For profit | 1 | 0 | 1 | 2011 |
| J. W. Goethe University | Academic/Hospital | 1 | 0 | 1 | 2011 |
| LCG Bioscience | For profit | 1 | 0 | 1 | 2009 |
| Pharmaceutical Research Associates, Inc. (PRA) | For profit | 1 | 0 | 1 | 2009 |
| University of Helsinki | Academic/Hospital | 1 | 0 | 1 | 2009 |
6 organizations
Page 1 / 1